Search clinical trials for: Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)

Total 40 results

CytoMed Therapeutics Pte Ltd
National University Hospital, Singapore

Not yet recruiting

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

Cancer | Malignancy | Relapsed Cancer | Refractory Cancer

Singapore
CytoMed Therapeutics Pte Ltd

Unknown

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Sarcoma | Nasopharyngeal Carcinoma | Gastric Cancer | Colorectal Cancer | Prostate Cancer | Triple Negative Breast Cancer

Malaysia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Southwest Hospital, China

Recruiting

A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Lymphoma | Leukemia

China
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University; NanJing PLA...

Completed

Chimeric Antigen Receptor T Cells Targeting Glypican-3

Hepatocellular Carcinoma

China
The Affiliated Hospital of Qingdao University

Recruiting

Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial

Gastric Cancer

China
The Affiliated Hospital of Qingdao University

Recruiting

XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation

Colon Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Zhengzhou University

Unknown

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Angioimmunoblastic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-negative | T Lymphoblastic Leukemia/Lymphoma | Extramedullary NK-T-cell Lymphoma, Nasal Type | Peripheral T-cell Lymphoma, Nonspecific | T-cell Lymphoblastic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Not yet recruiting

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Systemic Sclerosis | Immune Thrombocytopenia | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Primary Biliary Cholangitis
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Soochow University

Recruiting

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

T-ALL

China
Shanghai Tongji Hospital, Tongji University School...

Unknown

Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Multiple Myeloma

China
National Cancer Institute (NCI)

Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-cell | Lymphoma, Hodgkins | Lymphoma, Non-hodgkins

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Follicular Lymphoma | B Cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Plasma Cell Neoplasm | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Primary Cutaneous Follicle Centre Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Peking University People's Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Recruiting

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Unknown

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

Solid Tumor | CAR

China
Zhejiang University

Recruiting

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

Refractory Metastatic Colorectal Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Soochow University

Recruiting

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital; Shandong Cancer Hospital...

Recruiting

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

B7-H3-positive Relapsed/ Refractory Neuroblastoma

China
The Third Affiliated Hospital of Guangzhou Medical...
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

Refractory Metastatic Colorectal Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Sir Run Run Shaw Hospital

Completed

Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor

Multiple Myeloma

China
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Withdrawn

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
Dr. Melody Smith, MD, MS
Orca Biosystems, Inc.

Recruiting

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

Lymphoid Leukemia

United States
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Chinese PLA General Hospital

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
The Affiliated Hospital of Xuzhou Medical University
Xuzhou Medical University; IIT MediTech Co. Ltd

Recruiting

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Hepatocellular Carcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Progressive Disease | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Minimal Residual Disease | Recurrent Chronic Lymphocytic Leukemia | CD19 Positive | CD22...

United States
The First Affiliated Hospital of Soochow University
West China Hospital; Affiliated Hospital of Jiangnan University; The Affiliated... and other collaborators

Recruiting

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Mehrdad Abedi, MD
National Cancer Institute (NCI)

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
Crystal Mackall, MD
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | CD19 Positive

United States

Search clinical trials for: Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations